Global
Hemp Biotech Company Fosters Cannabinoid Education With Patients, Peers and the
Public
NEW
YORK, July 29, 2015 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTC:AXIM) CEO
George E. Anastassov, MD, DDS, MBA, proudly shared the Company's cannabinoid
delivery methods – including the world's first patented cannabinoid release chewing gum -
at the My CompassionChicago Cannabis Conference. The
three-day conference took place at Chicago's Navy Pier and focused on medical
cannabis and hemp education with patients, industry professionals and the
public.
"We
sincerely appreciate My Compassion hosting the 2nd Annual Chicago Cannabis Conference and including AXIM Biotech as a presenter on
cannabinoid delivery methods," states Dr. George E. Anastassov. "We
were able to educate healthcare and legal professionals, patients and the news
media. It was an invaluable experience and AXIM looks forward to supporting My
Compassion in the future."
Many
found the world's first patented hemp cannabinoid release chewing gum
intriguing. News features with AXIM include: ABC, NBC, Telemundo, WGN, and CBS.
Complete
use of the industrial hemp plant is at the core of the Company's business plan,
which aims to use the natural plant to benefit human health, while providing
clean alternative energy and delivering many other innovative applications. By
focusing efforts on unique proprietary delivery mechanisms for the introduction
of cannabinoids (e.g. CBD, CBG, CBN), AXIM Biotechnologies has charted a course
and is actively developing solutions for conditions for which there currently
are no effective treatments including: Parkinson's disease, Alzheimer's disease / dementia, ADHD (attention deficit hyperactivity
disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma,
IBD, IBS and Crohn's disease.
Dr.
Anastassov continues, "AXIM is committed to developing hemp-based
solutions for conditions with no known cure. Research of these conditions
including epilepsy, auto-immune disorders, and post-traumatic stress disorder /
PTSD, were discussed at the Chicago Cannabis Conference. Those that attended
gained access to valuable resources that are available today as well as
knowledge of what is to come in the near future."
AXIM
Biotech also creates strategic partnerships and acquisitions, allowing ongoing
research and development in the areas of functional foods, nutraceuticals,
pharmaceuticals, cosmetics, and clean energy – all derived from the industrial
hemp plant. For more information, visit AXIM Biotech's website.
To
arrange for media interviews, contact Andrew Hard, Public Relations
Spokesperson, at Andrew.Hard@CMWmedia.com or call
858-380-5478.
About
AXIM:
AXIM
Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology company
focusing on research, development and production of pharmaceutical,
nutraceutical and cosmetic products where we prioritize the well-being of our
customers while embracing a solid fiscal strategy. For more information, visit
the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING
DISCLAIMER
This
press release may contain certain forward-looking statements and information,
as defined within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe
Harbor created by those sections. This material contains statements about
expected future events and/or financial results that are forward-looking in
nature and subject to risks and uncertainties. Such forward-looking statements
by definition involve risks, uncertainties and other factors, which may cause
the actual results, performance or achievements of Axim Biotechnologies, Inc.
to be materially different from the statements made herein.
LEGAL
DISCLOSURE
AXIM
Biotechnologies does not sell or distribute any products that are in violation
of the United States Controlled Substances Act (US.CSA). The company does grow,
sell, and distribute hemp-based products.
CONTACT:
North American Address:
18 East 50th Street, 5
Floor
New York, NY 10022
+1 844 294 6246
European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The
Netherlands
+31 10 8209 227
http://www.einpresswire.com/article/278405688/axim-biotech-presents-patented-cannabinoid-delivery-methods-at-my-compassion-s-chicago-cannabis-conference
No comments:
Post a Comment